Atelerix has announced it has entered into a new distribution agreement with CliniSciences, a leading European player in the distribution and development of solutions for research and diagnostics.
Expanding on Atelerix’s global operational scale-up, the large territory, non-exclusive distribution agreement marks the company’s success in addressing the growing demand for non-cryogenic cell preservation solutions.
It will also enable penetration into the rapidly growing North African life sciences market.
CliniSciences is a recognised distributor for the life science research and diagnostics sector, specialising in reagents and instruments for immunology, cell biology and molecular biology.
The team has extensive experience connecting manufacturers of quality research and in vitro diagnostic products with researchers across Europe and is deeply embedded in biopharma and academic purchasing systems.
Through the new agreement, Atelerix will strengthen its distribution and technical support channels across Europe and also establish a presence in North Africa.
Atelerix has been pursuing an ambitious commercial strategy to proactively address market requirements for high-quality, temperature-sensitive products.
The company’s patented hydrogel-based solutions for preserving cell and tissue viability address critical challenges in the transport of temperature-sensitive biological samples.
These solutions remove the need for cryopreservation, which is associated with complicated shipping and handling protocols, high waste and energy consumption, as well as loss of cell viability.
“Europe is one of the world’s largest markets in life science research,” commented Wilfried Gay, Scientific Manager, CliniSciences.
“Atelerix’s patented hydrogels offer a unique approach to cell preservation and the transport of other temperature-sensitive biological substances to address obstacles in the logistics supply chain."
"We’re pleased to enter into this new partnership with Atelerix."
"It will allow us to bring these innovative cell preservation solutions to our customers and let them focus on what is most important to them – advancing ground-breaking research.”
Alastair Carrington, CEO, Atelerix, added: “With its established customer base and extensive team of technical experts across the continent, CliniSciences was the obvious choice of partner to expand our operations in Europe and enter the burgeoning North African life science market."
"Together, we are not only strengthening our presence in these key regions but also removing barriers to adoption – making it simpler for companies worldwide to access our products and integrate them into their own supply chain."
"The team and I look forward to working with CliniSciences to maximise value for customers, ensure our mutual success and enable effective support for global markets.”